What is Biosyntia?
Founded in 2012 by Hans Genee, Andreas Lausten, and Professor Morten Sommer, Biosyntia operates at the intersection of synthetic biology and industrial efficiency. The company specializes in developing microbes and fermentation processes that significantly reduce the time, cost, and risk associated with traditional bio-manufacturing. Recognized as one of Europe's most innovative SMEs, Biosyntia's core capabilities in strain engineering allow it to address complex manufacturing challenges across various sectors, positioning it as a critical player in the global transition toward a circular bioeconomy. The company's technological edge lies in its ability to accelerate the development cycle of bio-based products, providing a scalable alternative to conventional chemical synthesis.
How much funding has Biosyntia raised?
Biosyntia has raised a total of $13.6M across 2 funding rounds:
Angel/Seed
$1.9M
Other Financing Round
$11.7M
Angel/Seed (2015): $1.9M with participation from Novo A/S
Other Financing Round (2022): $11.7M led by European Circular Bioeconomy Fund, Sofinnova Partners, and Novo Seeds
Key Investors in Biosyntia
European Circular Bioeconomy Fund
ECBF is a specialist venture capital firm focused on the regenerative economy, investing in pioneering companies that aim to align economic growth with environmental sustainability.
Novo Seeds
Novo Seeds is a venture arm focused on early-stage life science investments, providing critical support to companies developing transformative biotechnological solutions.
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, acting as a major investor in life sciences and sustainable technologies.
What's next for Biosyntia?
With the recent influx of capital, Biosyntia is well-positioned to scale its operations and further commercialize its fermentation processes. The company's strategic roadmap likely involves expanding its industrial footprint and deepening its partnerships with global manufacturers seeking sustainable, bio-based alternatives. As the firm moves beyond its initial development phase, the focus will shift toward optimizing production yields and securing market share in high-value chemical and material sectors. By maintaining its commitment to rapid innovation and sustainable growth, Biosyntia is poised to remain at the forefront of the industrial biotech revolution, driving both economic value and environmental impact.
See full Biosyntia company page
